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Abstract Salsolinol (1-methyl-6,7-dihydroxy-1,2,3,4-tet-
rahydroisoquinoline), an endogenous compound present in
the brain, was suspected of participation in the etiopatho-
genesis of Parkinson’s disease, the most common serious
movement disorder worldwide. In this study, we evaluated
the effect of different (50, 100, and 500 lM) concentra-
tions of salsolinol on markers of glutamate-induced apop-
totic and neurotoxic cell damage, such as caspase-3
activity, lactate dehydrogenase (LDH) release, and the loss
of mitochondrial membrane potential. Biochemical data
were complemented with the cellular analysis, including
Hoechst 33342 and calcein AM staining, to visualize
apoptotic DNA-fragmentation and to assess cell survival,
respectively. The assessment of all investigated parameters
was performed in primary cultures of rat or mouse hippo-
campal and striatum cells. Our study showed that salsolinol
had biphasic effects, namely, at lower concentrations (50
and 100 lM), it demonstrated a distinct neuroprotective
activity, whereas in the highest one (500 lM) caused
neurotoxic effect. Salsolinol in concentrations of 50 and
100 lM significantly antagonized the pro-apoptotic and
neurotoxic effects caused by 1 mM glutamate. Salsolinol
diminished the number of bright fragmented nuclei with
condensed chromatin and increased cell survival in Hoe-
chst 33342 and calcein AM staining in hippocampal cul-
tures. Additionally, in the low 50 lM concentration, it
produced a significant inhibition of glutamate-induced loss
of membrane mitochondrial potential. Only the highest
concentration of salsolinol (500 lM) enhanced the gluta-
mate excitotoxicity. Ex vivo studies indicated that both
acute and chronic administration of salsolinol did not affect
the dopamine metabolism, its striatal concentration or a-
synuclein and tyrosine hydroxylase protein level in the rat
substantia nigra and striatum. Summarizing, the present
studies exclude possibility that salsolinol under physio-
logical conditions could be an endogenous factor involved
in the neurogenerative processes; conversely, it can exert a
protective action on nerve cells in the brain. These findings
may have important implications for the development of
the new strategies to treat or prevent neural degeneration.
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Introduction
Tetrahydroisoquinolines (THIQs) are endogenous sub-
stances which have been detected both in the rat and human
brain (Deng et al. 1996; Nagatsu 1997; Baum et al. 1999;
Haber et al. 1999; Naoi and Maruyama 1999; Musshoff et al.
2000). Because of their structural similarity to 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine that have been known as a
potential causative factor of Parkinson’s disease, tetrahy-
droisoquinoline alkaloids are considered to be endogenous
neurotoxins (Naoi et al. 1994; Maruyama et al. 1997;
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Nagatsu 1997; Naoi and Maruyama 1999). 1-Methyl-6,7-
dihydroxy-1,2,3,4-tetrahydroisoquinoline (salsolinol; its
chemical structure is shown in Fig. 1) is one of such com-
pounds. In vitro studies showed that salsolinol and especially
its derivative N-methyl-salsolinol caused apoptosis of
dopamine cells, although the molecular mechanism remains
unclear (Akao et al. 1999; Storch et al. 2000; Kim et al. 2001;
Naoi et al. 2002).
Salsolinol can be formed in the mammalian brain by
three different mechanisms: (1) via the nonenzymatic
Pictet–Spengler condensation of dopamine and aldehydes
producing salsolinol as two racemic isomers (R or S); (2)
by the nonenzymatic condensation of dopamine and
pyruvate yielding 1-carboxyl-tetrahydroisoquinoline, fol-
lowed by decarboxylation and reduction, which produces
(R)-salsolinol; (3) by selective synthesis of (R)-salsolinol
from dopamine and acetaldehyde, the level of which is
increased after ethanol intake. Apart from that salsolinol
has also been detected in certain beverages and food stuffs,
including soy sauce, cheese, chocolate, beef, beer, port
wine, and dried bananas (Niwa et al. 1989; Strolin
Benedetti et al. 1989; Deng et al. 1997; Cai and Liu 2008).
Salsolinol has been found and demonstrated recently to
play an essential physiological role by several groups of
scientists pointing to its significant regulatory role in the
prolactin release in the neuro-intermediate lobe of the brain
(Toth et al. 2001; Homicsko et al. 2003; Naoi et al. 2004;
Szekacs et al. 2007; Hashizume et al. 2010; Jin et al. 2014)
or the sympathoadrenal system activity (Bodnar et al.
2004).
On the other hand, salsolinol was also found to be
involved in neurotoxicity processes altering the normal
function and survival of dopamine neurons. The compound
caused oxidative stress and acted as an inhibitor of mito-
chondrial energy supply, and might be responsible for
some neurological and psychiatric disorders (Niwa et al.
1993; Nagatsu 1997). Consequently, salsolinol has been
proposed to be an endogenous compound participating in
the ethiopathogenesis of Parkinson’s disease (Nagatsu
1997; Naoi et al. 1997; Antkiewicz-Michaluk et al. 1998;
Lorenc-Koci et al. 2000; Antkiewicz-Michaluk 2002;
Mravec 2006). However, it should be noticed that in clin-
ical research carried out on the lumber cerebrospinal fluid
(CSF) samples taken from early and advanced parkinsonian
patients, salsolinol concentrations were significantly
enhanced only in patients with signs of dementia (Ant-
kiewicz-Michaluk et al. 1997).
In that light the question arises whether neurotoxic
effect of salsolinol in the brain is connected only with
dopaminergic structures. It would be also interesting to
examine whether in vitro effects of salsolinol may corre-
spond with the ex vivo experiments.
In order to solve these problems, we investigated in the
present study the effect of salsolinol on glutamate-evoked
neurotoxicity in the primary cultures of mouse and rat
brain. The effects of different salsolinol concentrations on
apoptosis markers in in vitro models in rodents and after its
in vivo administration on dopamine metabolism in the rat
striatum and substantia nigra were assessed.
Materials and Methods
Animals and Treatment
The ex vivo experiments were carried out on male Wistar
rats with initial body weight of 220–240 g. The animals
were kept under standard laboratory conditions with free
access to standard laboratory food and tap water, at room
temperature of 22 C with an artificial day cycle (12/12 h,
light on at 7 a.m.).
The rats were administrated salsolinol at a dose of
100 mg/kg intraperitoneally (i.p.) once or chronically for
14 consecutive days. Control rats were treated with an
appropriate solvent. Animals were killed by decapitation 2
or 24 and 3 or 24 h after the last drug injection to assay the
level of dopamine and its metabolites, and a-synuclein and
tyrosine hydroxylase, respectively. To perform the above
analysis, the substantia nigra and striatum were isolated
from the brain. All experiments were performed between
9.00 a.m. and 4.00 p.m.
All the procedures were carried out in accordance with
the National Institutes of Health Guide for the Care and
Use of Laboratory Animals and were granted an approval
from the Bioethics Commission as compliant with Polish
Law. All the experimental procedures were approved by
the Local Bioethics Commission of the Institute of Phar-
macology, Polish Academy of Sciences in Cracow.
Drugs
Salsolinol (1-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroiso-
quinoline; Sigma-Aldrich) was dissolved in 0.9 % NaCl
solution. Glutamic acid was obtained from Sigma-Aldrich
(St. Louis, MO, USA), whereas Hoechst 33342 and calcein
AM were purchased from Molecular Probes (Eugene, OR,
USA). The chemical structure of the salsolinol is shown in
Fig. 1.
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Primary Hippocampal and Striatum Cell Cultures
Hippocampal and striatum tissues for primary cultures
were collected from Wistar rat or Swiss mouse embryos
(Charles River, Germany) on 15th–17th day of gestation
and were cultured essentially as described earlier (Kajta
et al. 2007, 2009a). Animal care followed official gov-
ernmental guidelines, and all efforts were made to mini-
mize the number of animals used and their suffering. All
procedures were carried out in accordance with the
National Institutes of Health Guidelines for the Care and
Use of Laboratory Animals and were approved by the
Bioethics Commission as being compliant with Polish Law
(21 August 1997). The cells were suspended in estrogen-
free neurobasal medium supplemented with B27 and plated
at a density of 2.5 9 105 cell/cm2 onto poly-ornithine-
coated (0.01 mg per ml) multi-well plates. The cultures
were maintained at 37 C in a humidified atmosphere
containing 5 % CO2 for 7 days in vitro (DIV) prior to
experimentation. The level of astrocytes in cell cultures, as
determined by the content of intermediate filament protein
glial fibrillary acidic protein (GFAP), did not exceed 10 %
(Kajta et al. 2004, 2014).
Treatment
Primary hippocampal and striatum cell cultures were
exposed to glutamic acid (1 mM), salsolinol (50, 100,
500 lM) or glutamic acid, and salsolinol for 24 h. To
avoid unspecific effects in our study, salsolinol was used in
the concentrations which did not affect the control level of
caspase-3 activity and LDH release. All the compounds
were originally dissolved in dimethyl sulfoxide (DMSO)
and then further diluted in culture medium so that DMSO
concentrations remained below 0.1 %.
Identification of Apoptotic Cells
In order to visually assess apoptotic changes in hippo-
campal cells, Hoechst 33342-staining was applied 24 h
after initial treatment, as described previously (Kajta et al.
2007, 2013). Before dye application, hippocampal cells
cultured on glass cover slips were washed with 10 mM
phosphate-buffered saline (PBS) and exposed to Hoechst
33342 (0.6 mg/ml), at room temperature (RT) for 5 min.
Cells with bright blue fragmented nuclei showing con-
densed chromatin were identified as apoptotic cells.
Qualitative analysis was performed using a fluorescence
microscope (Leica Microsystems Wetzlar GmbH, Wetzlar,
Germany) connected to a CoolSnap camera (Vision Sys-
tems GmbH, Puchheim, Germany) with the use of Meta-
Morph Software.
We counted fragmented nuclei and presented them as a
percentage of the vehicle-treated control. The total number
of nuclei in each experimental group ranged between 480
and 530. At least three slides were made from three inde-
pendent culture platings.
Staining with Calcein AM
Staining with calcein AM was used to measure intracellular
esterase activity in hippocampal cultures 24 h after initial
treatment (Kajta et al. 2007). To block esterase activity
present in the growth media, cells were washed with PBS.
The cells grown on glass cover slips were then incubated in
2 lM calcein AM in PBS at RT for 10 min. Cells with
bright yellow cytoplasm were identified as live cells. A
fluorescence microscope (Leica Microsystems Wetzlar
GmbH, Wetzlar, Germany) connected to a CoolSnap
camera (Vision Systems GmbH, Puchheim, Germany) with
MetaMorph software was used for qualitative analyses.
Assessment of Mitochondrial Membrane Potential
The mitochondrial membrane potential was evaluated with
the JC-1 Assay Kit, which utilizes a cationic dye 5,50,6,60-
tetrachloro-1,10,3,30-tetraethylbenzimidazolylcarbo-cyanine
iodide. In healthy cells, the dye aggregates and stains the
mitochondria bright red, whereas in apoptotic cells, the
mitochondrial cytoplasm contains a green fluorescent
monomeric form (Hirsch et al. 1998). The assessment of loss
of mitochondrial membrane potential, which is a hallmark of
apoptosis, was performed in the hippocampal cultures trea-
ted for 6 h with glutamic acid alone or in combination with
salsolinol (50, 500 lM). The cells were incubated with JC-1
solution for 25 min, and red (550/600 nm) and green (485/
535 nm) fluorescences were measured with an Infinite
M1000 microplate reader (Tecan, Austria). The data were
analyzed with I-control software, normalized to the fluo-
rescence in vehicle-treated cells, and expressed as the mean
red to green fluorescence ratio ± SEM of three to four
independence experiments. The fluorescence of blanks, i.e.,
no-enzyme controls, was subtracted from each value.
Assessment of Caspase-3 Activity
Caspase-3 activity was assayed according to Nicholson et al.
(1995), in samples treated for 24 h with glutamic acid (1 mM)
alone or in combination with the test compound. The assess-
ment of caspase-3 activity was performed as previously
described (Kajta et al. 2009b). Cell lysates were incubated at
36 C with a colorimetric substrate preferentially cleaved by
caspase-3: Ac-DEVD-pNA (N-acetyl-asp-glu-val-asp-p-
nitro-anilide). The levels of p-nitroanilide were monitored
continuously over 60 min with a Multiskan Spectrum
302 Neurotox Res (2015) 27:300–313
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Microplate Spectrophotometer (Thermo Labsystems, Vantaa,
Finland). Data were analyzed with Ascent Software, nor-
malized to the absorbance in vehicle-treated cells, and
expressed as the mean percentage of control ± SEM of three
to four independent experiments. Absorbance of blanks, i.e.,
no-enzyme controls, was subtracted from each value.
Measurement of Lactate Dehydrogenase Activity
In order to estimate cell death, the level of lactate dehy-
drogenase (LDH) released from damaged cells into culture
media was measured 24 h after treatment with glutamic acid
(1 mM) and salsolinol (50, 100, and 500 lM). LDH release
was measured as previously described (Kajta et al. 2004).
Cell-free culture supernatants were collected from each well
and incubated with the appropriate reagent mixture accord-
ing to the manufacturer’s instructions (Cytotoxicity Detec-
tion Kit) at RT for 30–60 min depending on the reaction
progress. The intensity of red color formed in the assay
mixture and measured at a wavelength of 490 nm was
proportional to LDH activity and to the number of damaged
cells. Data were normalized to the activity of LDH released
from vehicle-treated cells (100 %) and expressed as the
mean percent of the control of three to four independent
experiments. The total LDH release was determined in the
cell cultures treated with 1 % Triton X-100 for 24 h. The
total LDH release reached a value of 1.108 ± 0.154 U/h/
100 lg protein. In control cultures, the absolute value of
LDH activity was 0.270 ± 0.011 U/h/100 lg protein and
was similar to that obtained by Mytilineou et al. (1998).
HPLC Analysis of the Concentration of Dopamine
and Its Metabolites
The animals were killed by decapitation 2 or 24 h after the last
salsolinol (100 mg/kg i.p.) injection. The brains were rapidly
removed and dissected on an ice-cold glass plate. The sub-
stantia nigra and striatum were isolated and immediately fro-
zen on solid CO2 (-80 C) until used for biochemical assay.
Dopamine (DA) and its metabolites, the intraneuronal, 3,4-
dihydroxyphenylacetic acid (DOPAC); the extraneuronal,
3-methoxytyramine (3-MT) and the final metabolite; and
homovanillic acid (HVA) were assayed by means of high-
performance liquid chromatography (HPLC) with electro-
chemical detection (ED). The tissue samples were weighted
and homogenized in ice-cold 0.1 M trichloroacetic acid con-
taining 0.05 mM ascorbic acid. After centrifugation
(10,0009g, 5 min), the supernatants were filtered through RC
58 0.2 lm cellulose membranes (Bioanalytical Systems, West
Lafayette, IN, USA). The chromatograph HP 1050 (Hewlett-
Packard, Golden, CO, USA) was equipped with Hypersil
columns BDS-C18 (4 9 100 mm, 3 lm). The mobile phase
consisted of 0.05 M citrate–phosphate buffer, pH 3.5; 0.1 mM
EDTA; 1 mM sodium octyl sulfonate; and 3.5 % methanol.
The flow rate was maintained at 1 ml/min. Dopamine and their
metabolites were quantified by peak area comparisons with
standards run on the day of analysis (ChemStation, Hewlett-
Packard software computer program).
Western Blot Analysis of a-synuclein and Tyrosine
Hydroxylase Protein
After dissection, the substantia nigra was immediately frozen
on dry ice and stored at -80 C until analysis. The tissue was
homogenized on ice in 20 volumes of RIPA buffer (150 mM
NaCl, 1 % NP-40, 0.5 % sodium deoxycholate, 0.1 % SDS,
50 mM Tris, pH 8.0) containing a mixture of protease inhib-
itors (Pierce). Protein concentration in the supernatants was
determined using bicinchoninic acid protein assay kit (Pierce).
Afterwards, the samples containing 5 lg of total protein were
fractionated by 10 % sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE), according to Laemnili
(1970), and processed in order to detect a-synuclein or tyro-
sine hydroxylase (TH). Proteins from the resolved gels were
then transferred to nitrocellulose membranes (Sigma). Non-
specific binding sites were blocked overnight at 4 C by a 3 %
BSA in Tris-buffered saline with 0.5 % Tween 20 (TBS-T)
and incubated for 2 h with a mouse monoclonal anti-a-syn-
uclein antibody (BD Transduction Laboratories, dilution
1:2000) or mouse monoclonal anti-TH antibody (Millipore,
dilution 1:4000) in 1 % BSA at RT. After three subsequent
washes in TBS-T, membranes were processed according to
the standard BM Chemiluminescence Western Blotting Kit
protocol (Roche Applied Science). Following immunoblot
visualization, membranes were blocked with 5 % non-fat dry
milk in TBS for 10 min at RT and dried on absorbent filter
paper. Afterwards, blots were erased in 62.5 mM Tris pH 6.8,
2 % SDS, 100 mM 2-mercaptoethanol for 30 min at 50 C,
washed twice with TBS, and blocked overnight with 5 % non-
fat dry milk in TBS at 4 C. As a control for level normali-
zation, the erased blots were processed with mouse mono-
clonal antib-actin antibody (Santa Cruz Biotechnology, Inc.,
dilution 1:10000), as described above.
The amounts of protein per lane as well as antibody
concentrations were optimized in pilot studies so that
threefold differences in protein content were linearly
reflected on the immunoblots.
The signals were visualized and quantified by the densito-
metric analysis with the FUJI-LAS 4000 system and Fuji Multi
Gage Software. The results are presented as a percentage of the
control of the analyzed protein: b-actin ratio ± SEM.
Data Analysis
Statistical tests were performed on raw data expressed as the
mean arbitrary absorbance or fluorescence units per well
Neurotox Res (2015) 27:300–313 303
123
containing 50,000 cells (measurements of caspase-3, LDH,
mitochondrial potential). A one-way analysis of variance
(ANOVA) was used to determine overall significance. Dif-
ferences between control and experimental groups were
assessed with a post hoc Newman–Keuls test. Significant
differences were marked as follows: *P \ 0.05, **P \ 0.01,
***P \ 0.001 (versus control group); #P \ 0.05, ##P \ 0.01,
###P \ 0.001 (versus glutamic acid group).
Following Shapiro–Wilk tests, for normality, the data of
neurochemical studies were compared using Student’s
t test for independent groups (control versus salsolinol
100 mg/kg group). The null hypothesis of the lack of dif-
ferences between the investigated groups was adopted
(P [ 0.05). The alternative hypothesis commanded the
existence of differences between groups.
The total DA catabolism rate was assessed from the ratio
of the final DA metabolite concentration, HVA to DA
concentration and expressed as the catabolic rate index
(HVA)/(DA) 9 100; the rate of DA MAO-dependent oxi-
dation as the ratio: (DOPAC)/(DA) 9 100; the rate of DA
COMT-dependent O-methylation as the ratio: (3-MT)/
(DA) 9 100; and the factor of DA re-uptake inhibition as
the ratio: (3-MT)/(DOPAC) 9 100. The indices were cal-
culated using concentrations from individual tissue sam-
ples (Antkiewicz-Michaluk et al. 2001).
Statistical significance of the data from Western blot
analysis was assessed using a one-way analysis of variance
(ANOVA) followed (if significant) by Tukey test for post
hoc comparison with the control (saline) group.
Results
The Effects of Salsolinol on Glutamate-Induced
Caspase-3 Activity and LDH Release in Rat
Hippocampal and Mouse Striatum Cultures
Rat Hippocampal Cultures
In hippocampal cultures exposed to 1 mM glutamic acid for
24 h, the activity of caspase-3 increased by 30 % (P \ 0.01)
(Fig. 2a). In the presence of glutamate and salsolinol in the
low concentrations (50 and 100 lM), the activity of caspase-3
was diminished by amount 20 % compared to the glutamate-
induced value (P \ 0.001). In contrast, the highest dose of
salsolinol (500 lM) significantly intensified glutamate-acti-
vated caspase-3 (up to 125 %, P \ 0.001) (Fig. 2a).
LDH release increased with the duration of glutamic
acid treatment by 54 % (P \ 0.01) (Fig. 3a). Salsolinol
was effective in the lower concentrations (50 and
100 lM)—it inhibited glutamate-induced LDH release by
amount 25–27 % (P \ 0.001). After 24 h of treatment,
salsolinol increased glutamate-induced LDH release only
at the highest concentration of 500 lM (up to 123 %,
P \ 0.01) (Fig. 3a).
Mouse Striatum Cultures
In striatum cultures exposed to 1 mM glutamic acid for
24 h, the activity of caspase-3 increased by 40 %
(P \ 0.01) (Fig. 2b). Salsolinol administration in both
concentrations 50 and 500 lM inhibited the activity of
caspase-3 by amount 17 % and 38 %, respectively (com-
pared to the glutamic acid effects, P \ 0.001) (Fig. 2b).
LDH release increased with the duration of glutamic acid
treatment by 33 % (P \ 0.01) (Fig. 3b). Both concentrations
of salsolinol (low—50 lM, the highest—500 lM) effec-
tively inhibited glutamate-induced LDH release by amount
33 and 44 % (P \ 0.001) (Fig. 3b), respectively.
The Effects of Salsolinol on Glutamate-Induced
Changes in Calcein AM and Hoechst 33342 Staining
in Hippocampal Cultures
A continuous 24 h exposure of hippocampal cultures to
glutamic acid (1 mM) diminished the density of living cells
Fig. 2 The effect of salsolinol on glutamate-induced caspase-3
activity in a rat hippocampal and b mouse striatum cultures. Cells
were treated either with glutamic acid (1 mM) or salsolinol (50, 100,
and 500 lM) alone or in combination. The results are presented as a
percentage of control. Each bar represents the mean of three or four
independent experiments ± SEM. The number of replicantes is each
experiment ranged from 5 to 8. ***P \ 0.001 versus control cultures;
###P \ 0.001 versus cultures exposed to glutamic acid
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on seven DIV, as indicated by the decreased number of
cells with light-colored cytoplasm (Fig. 4b). Treatment
with glutamic acid substantially enhanced the number of
bright fragmented nuclei with condensed chromatin (by
amount 97 % vs. control group; P \ 0.001), which is
typical of cells undergoing apoptosis (Figs. 4b, 5).
Co-treatment with salsolinol (50 lM) normalized the
number of healthy living cells and diminished the number
of fragmented nuclei (P \ 0.001) (Figs. 4c, 5). In contrast
to this, co-treatment with the highest dose of salsolinol
(500 lM) enhanced the glutamate-induced changes in
Hoechst 33342 and calcein AM staining in the hippocam-
pal cultures (Figs. 4d, 5).
The Effects of Salsolinol on Glutamate-Induced Loss
of Mitochondrial Membrane Potential in Mouse
Hippocampal Cultures
Six-hour exposure of hippocampal cultures to glutamic
acid (1 mM) caused over 66 % loss of the mitochondrial
membrane potential in the neuronal cells (P \ 0.001)
(Fig. 6). Salsolinol used in a low concentration (50 lM) in
primary hippocampal cultures did not affect the mito-
chondrial membrane potential but produced two-phase
effect on glutamate-induced toxicity. The highest dose of
salsolinol (500 lM) produced the effect similar to gluta-
mate (P \ 0.001). Salsolinol in investigated concentration
did not cause statistically significant changes in the effect
of glutamate on the loss of mitochondrial membrane
potential (Fig. 6).
The Effects of Salsolinol on Dopamine, Its Metabolites
Concentration in Rats, and the Rate of Dopamine
Metabolism in Substantia Nigra and Striatum (Tables 1, 2)
Substantia Nigra
The statistical analysis showed no effect of acute admin-
istration of salsolinol on dopamine and its metabolites
concentrations, and the rate of dopamine metabolism in
substantia nigra (Table 1a).
2 h withdrawal after chronic administration revealed no
differences in dopamine and its metabolites levels between
investigated groups. Only dopamine catabolism (MAO-
dependent oxidation) DOPAC/DA was slightly inhibited
(P \ 0.05) (Table 1b).
After 24 h withdrawal, a slight inhibition of the HVA
level was observed (P B 0.05) in substantia nigra. The
concentration of dopamine and the rate of its metabolism
were not changed (Table 1c).
Striatum
The statistical analysis revealed no changes in dopamine
levels in striatum after acute and chronic (2 and 24 h
withdrawal) salsolinol administration (Table 2a–c). Statis-
tically significant elevation in DOPAC concentration was
observed after acute (P \ 0.01) and chronic (2 h with-
drawal) salsolinol injection (Table 2a, b).
Acute administration of salsolinol slightly increased the
rate of final dopamine metabolism HVA/DA (P B 0.01)
and dopamine catabolism (MAO-dependent oxidation)
DOPAC/DA (P \ 0.05).
Additionally, 2 h withdrawal after chronic administra-
tion of salsolinol slightly inhibited dopamine catabolism
(COMT-dependent O-methylation) 3-MT/DA (Table 2b).
No more changes in dopamine, its metabolites concentra-
tions, and the rate of dopamine metabolism were observed
after acute and chronic administration of salsolinol in
striatum.
Fig. 3 The effect of salsolinol on glutamate-induced release of LDH
in a rat hippocampal and b mouse striatum cultures. Cells were
treated either with glutamate (1 mM) alone or in combination with
salsolinol (50, 100, or 500 lM). The results are presented as a
percentage of control. Each bar represents the mean of three to four
independent experiments ± SEM. The number of replicantes in each
experiment ranged from 5 to 8. **P \ 0.01 versus control cultures;
#P \ 0.05, ###P \ 0.001 versus the cultures exposed to glutamic acid
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The Effects of Acute and Chronic Salsolinol Administration
on the a-synuclein Level in Rat Substantia Nigra
as Measured 3 and 24 h After the Last Dose. Ex Vivo Study
Both acute and chronic (14 consecutive days) administra-
tions of salsolinol (100 mg/kg i.p.) did not change the level
of a-synuclein in rats substantia nigra measured 3 or 24 h
after the last dose (Fig. 7a, b).
The Effects of Acute and Chronic Salsolinol Administration
on the Tyrosine Hydroxylase Level in Rat Substantia Nigra
as Measured 3 and 24 h After the Last Dose. Ex Vivo Study
Both acute and chronic (14 consecutive days) administra-
tions of salsolinol (100 mg/kg i.p.) did not change the level
of tyrosine hydroxylase in rats substantia nigra measured 3
or 24 h after the last dose (Fig. 8a, b).
Fig. 4 The effect of salsolinol
(50 or 500 lM) on glutamate-
induced (1 mM) changes in
calcein AM (first column) and
Hoechst 33342 (second column)
staining in rat hippocampal
cultures at seven DIV, examined
24 h post-treatment. a Control,
b glutamate (1 mM),
c glutamate
(1 mM) ? salsolinol (50 lM),
d glutamate
(1 mM) ? Salsolinol (500 lM).
Cells were cultured on glass
cover slips, washed with 10 mM
PBS, and exposed to 2 lM
calcein AM at RT for 10 min.
Cells were then rewashed and
incubated with Hoechst 33342
(0.6 lg/ml) at RT for 5 min.
Cells with bright fragmented
nuclei showing condensed
chromatin were identified as
undergoing apoptosis, whereas
cells with light-colored
cytoplasm were identified as
living cells. Hoechst 33342 stain
is one of the most common used
parts of a family of blue
fluorescent dyes used to stain
DNA. (For interpretation of the
references to color in this figure
legend, the reader is referred to
the web version of this article)
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Discussion
The main finding of this paper is that salsolinol produced
concentration-dependent opposing effects on apoptosis
markers assessed in in vitro studies in the primary hippo-
campal cultures of mice and rats. Salsolinol in the low
investigated concentrations (50 and 100 lM) possessed
neuroprotective activity; however, a tenfold increase in its
concentration (500 lM) seemed to be neurotoxic, and
significantly intensified glutamate-induced neurotoxicity.
Estimation of the levels of two proteins: a-synuclein and
tyrosine hydroxylase after chronic in vivo administration of
salsolinol did not reveal its neurotoxic effects on dopamine
neurons in the substantia nigra. Similarly to this, ex vivo
studies did not show any significant adverse effects of
salsolinol on the levels of dopamine and its metabolites in
the nigrostriatal system: substantia nigra and striatum.
Salsolinol, a catechol isoquinoline, has invited consid-
erable attention due to its structural similarity to dopami-
nergic neurotoxins, like MPTP. Its high endogenous level
in the brain of parkinsonian patients might suggest its
possible association with the disease process (Nagatsu and
Yoshida 1988; Kotake et al. 1995; Antkiewicz-Michaluk
et al. 2001). Salsolinol is considered to be synthesized
through a condensation reaction between dopamine and
acetaldehyde in the human and mammalian brain. A low
concentration of salsolinol was detected in normal human
cerebrospinal fluid (Moser and Kompf 1992), brain and
urine (Dostert et al. 1989). In contrast, both parkinsonian
patients treated with L-DOPA and chronic alcoholics
showed a significant elevation in the concentration of
salsolinol in CSF and urine (Cohen and Collins 1970;
Sandler et al. 1973; Collins et al. 1979; Moser and Kompf
1992). Besides endogenous formation, salsolinol has also
been detected in certain beverages and food stuffs,
including soy sauce, chocolate, beer, port wine, and dried
bananas.
The ability of salsolinol to cross the blood–brain barrier
(BBB) has been the subject of interest of several research
groups, although, unfortunately, the results obtained so far are
not conclusive. Initially, it was commonly thought that salso-
linol as a catecholamine and its analogs were not able to migrate
Fig. 5 The effect of salsolinol (50 or 500 lM) on glutamate-induced
(1 mM) changes in Hoechst 33342 staining in rat hippocampal
cultures—quantification. Fragmented nuclei were counted and pre-
sented as a percentage of the vehicle-treated control. The total number
of nuclei in each experimental group ranged between 480 and 530. At
least three slides were made from three independent culture platings
Fig. 6 The effect of salsolinol on glutamate-induced loss of mito-
chondrial membrane potential in mouse hippocampal cultures.
Primary hippocampal cultures were treated with glutamic acid
(1 mM) or salsolinol (50 or 500 lM) alone or in combination, for
6 h. The mitochondrial membrane potential was detected with JC-1
Assay Kit. The results were normalized to the fluorescence in vehicle-
treated cells and expressed as red to green fluorescence ratio. Each bar
represents the mean of three to four independent experi-
ments ± SEM. The number of replicantes in each experimental
ranged from 5 to 8. ***P \ 0.001 versus control cultures; #P \ 0.05,
##P \ 0.01 versus the cultures exposed to glutamic acid
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Table 1 The effect of salsolinol on dopamine, its metabolites concentration in rats, and the rate of dopamine metabolism in substantia nigra
Treatment DA DOPAC 3-MT HVA HVA/DA DOPAC/DA 3-MT/DA
a: Salsolinol—acute
Control 889 ± 125 212 ± 84 49 ± 11 106 ± 37 12 ± 4 24 ± 11 6 ± 1
Salsolinol 773 ± 100 191 ± 38 79 ± 52 94 ± 21 14 ± 3 24 ± 3 7 ± 2
t 1.77 0.64 -1.36 0.78 -1.20 0.15 -1.83
df 12 12 12 12 12 12 12
P N.S. N.S. N.S. N.S. N.S. N.S. N.S.
b: Salsolinol—chronic, 2h withdrawal
Control 845 ± 162 215 ± 49 74 ± 18 152 ± 30 19 ± 5 25 ± 2 9 ± 1
Salsolinol 913 ± 156 198 ± 37 64 ± 9 147 ± 39 16 ± 3 22 ± 3* 7 ± 2
t -0.80 0.74 1.33 0.27 1.11 2.62 2.07
df 12 12 12 12 12 12 12
P N.S. N.S. N.S. N.S. N.S. P \ 0.05 N.S.
c: Salsolinol—chronic, 24h withdrawal
Control 795 ± 250 212 ± 48 72 ± 18 150 ± 36 20 ± 6 27 ± 4 10 ± 4
Salsolinol 675 ± 126 191 ± 38 60 ± 12 104 ± 44* 16 ± 7 29 ± 5 9 ± 3
t 1.13 0.88 1.46 2.18 1.24 -0.62 0.21
df 12 12 12 12 12 12 12
P N.S. N.S. N.S. P B 0.05 N.S. N.S. N.S.
Control group received saline. Salsolinol was administrated in a dose 100 mg/kg i.p. once (acute) or for 14 consecutive days (chronic); N = 6–8
animals per group. The concentrations of dopamine and its metabolites were measured in ng/g wet tissue. The data are the mean ± SD.
Following Shapiro–Wilk test, for normality, the data were compared using Student’s t test for independent group (control vs. salsolinol 100 mg/
kg group). The null hypothesis of the lack of differences between the investigated groups was adopted (P [ 0.05). The alternative hypothesis
commanded the existence of differences between groups; statistical significance: * P \ 0.05, ** P \ 0.01
Table 2 The effect of salsolinol on dopamine, its metabolites concentration in rats, and the rate of dopamine metabolism in striatum
Treatment DA DOPAC 3-MT HVA HVA/DA DOPAC/DA 3-MT/DA
a: Salsolinol—acute
Control 9,042 ± 1,054 1,238 ± 62 438 ± 48 675 ± 113 7.4 ± 0.7 14 ± 2 4.8 ± 0.2
Salsolinol 9,457 ± 1,008 1,584 ± 227** 689 ± 384 897 ± 281 11 ± 3** 16 ± 2* 5.1 ± 0.5
t -0.70 -3.60 -1.57 -1.82 -6.28 -2.32 -1.02
df 10 12 12 12 12 12 12
P N.S. P B 0.01 N.S. N.S. P B 0.01 P \ 0.05 N.S.
b: Salsolinol—chronic, 2h withdrawal
Control 10,439 ± 815 1467 ± 131 554 ± 58 1,149 ± 83 11 ± 1.3 14 ± 2 5.3 ± 0.5
Salsolinol 11,415 ± 1044 1,789 ± 327* 514 ± 26 1,377 ± 296 12 ± 2.1 16 ± 2 4.5 ± 0.5*
t -1.95 -2.42 1.65 -1.96 -1.03 -1.52 2.77
df 12 12 12 12 12 12 12
P N.S. P \ 0.05 N.S. N.S. N.S. N.S. P \ 0.05
c: Salsolinol—chronic, 24h withdrawal
Control 13,843 ± 1,626 1,728 ± 178 665 ± 62 1,263 ± 179 9 ± 2 13 ± 1 4.8 ± 0.3
Salsolinol 13,808 ± 1,222 1,719 ± 312 679 ± 127 1,169 ± 405 8 ± 2 12 ± 1 4.9 ± 0.8
t 0.05 0.06 -0.26 0.56 0.75 0.25 -0.30
df 12 12 12 12 12 12 12
P N.S. N.S. N.S. N.S. N.S. N.S. N.S.
Control group received saline. Salsolinol was administrated in a dose 100 mg/kg i.p. once (acute) or for 14 consecutive days (chronic); N = 6–8
animals per group. The concentrations of dopamine and its metabolites were measured in ng/g wet tissue. The data are the mean ± SD.
Following Shapiro–Wilk test, for normality, the data were compared using Student’s t test for independent group (control vs. salsolinol 100 mg/
kg group). The null hypothesis of the lack of differences between the investigated groups was adopted (P [ 0.05). The alternative hypothesis
commanded the existence of differences between groups; statistical significance: * P \ 0.05, ** P \ 0.01
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from blood into the brain, despite the fact that contradictory
results were reported (Origitano et al. 1981; Sjo¨quist and
Magnuson 1980). Several authors have reported that systemi-
cally administrated salsolinol is capable of altering behavior
(Naoi et al. 1996; Antkiewicz-Michaluk et al. 2000; Matsuzawa
et al. 2000; Vetulani et al. 2001), which indirectly suggests that
salsolinol could cross the BBB.
A number of in vitro studies have demonstrated that
glutamate is a potent neurotoxin capable of destroying
neurons by apoptosis (Froissard and Duval 1994; Kajta et al.
2007; 2013; Wa˛sik et al. 2014). For this reason, the gluta-
mate model of neurotoxicity was used in the presented paper
as a good model to study programmed cells death. As
investigated so far, exposure to glutamic acid has been
associated with an increase in cytosolic Ca2? in the cells
(Atlante et al. 2001), and a long-time exposure to glutamate
resulted in permanent damage of mitochondria, which
occurred simultaneously with a high mitochondrial ROS
production (Beal et al. 1997). As presented in this paper,
glutamic acid (1 mM) significantly increased the caspase-3
activity (Fig. 2a, b). In rat hippocampal cultures, the lower
investigated concentrations of salsolinol (50 and 100 lM)
diminished this apoptotic marker, while its highest dose
(500 lM) significantly potentiated the glutamic acid effect
on caspase-3 activity (Fig. 2a). Analogous effects were
observed for LDH release (Fig. 3a), which suggests that
salsolinol has a clear biphasic effects; at lower concentra-
tions (50 and 100 lM) it demonstrated the neuroprotective
activity, whereas in the highest dose (500 lM), it caused
neurotoxic effect. Additionally, in mouse striatum cultures,
both investigated doses of salsolinol (50 and 500 lM)
revealed the neuroprotective function (Figs. 2b, 3b). In
contrast to the previous studies, we investigated for the first
time whether salsolinol can destroy nondopaminergic
structures, e.g., the hippocampus. It is composed of different
kinds of neurons and contains a high proportion of gluta-
matergic and small amount of dopaminergic neurons. For
this reason, it is a very sensitive structure to the glutamate-
induced toxicity and is a good model for investigation of
apoptosis.
Fig. 7 The effects of acute and chronic salsolinol administration on
the a-synuclein level in the substantia nigra, a 3 h and b 24 h
withdrawal. Salsolinol was administrated acute or chronic at dose
100 mg/kg i.p. during 14 consecutive days. The control group was
treated with saline. The rats were decapitated 3 or 24 h after last
injection, respectively. The results are expressed as the mean ± SEM
of six samples (n = 6 animals per group). Data were analyzed by
means of one-way ANOVA followed by Tukey test. Statistical
significance: *P \ 0.05; **P \ 0.01 versus control group
Fig. 8 The effects of acute and chronic salsolinol administration on
the tyrosine hydroxylase level in the substantia nigra, a 3 and b 24 h
withdrawal. Salsolinol was administrated acute or chronic at dose
100 mg/kg i.p. during 14 consecutive days. The control group was
treated with saline. The rats were decapitated 3 or 24 h after last
injection, respectively. The results are expressed as the mean ± SEM
of six samples (n = 6 animals per group). Data were analyzed by
means of one-way ANOVA followed by Tukey test. Statistical
significance: *P \ 0.05; **P \ 0.01 versus control group
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Storch et al. (2000) concluded that salsolinol was toxic to
dopaminergic neuroblastoma SH-SY5Y cells by blocking
the cellular energy supply via inhibition of mitochondrial
complex II activity. The latter authors found that incubation
of human SH-SY5Y dopaminergic neuroblastoma cells with
salsolinol resulted in a rapid, dose- and time-dependent
decrease in the intracellular level of ATP and ATP/ADP ratio
of intact cells (Wanpen et al. 2004). Other in vitro studies
showed that salsolinol induced specific changes in cellular
energy metabolism, similar to those caused by MPP?, which
consistently preceded cell death (Storch et al. 2000). As
Morikawa et al. (1998) reported, salsolinol inhibited mito-
chondrial complex II activity. It caused a rapid loss of
intracellular ATP and maximal turnover of glycolysis
without compensating for fast energy depletion. Addition-
ally, the blockade of complex II did not change the level of
NADH. Selective binding of salsolinol was confirmed not
only in dopaminergic structures, such as the striatum, but
also in the pituitary gland, cortex, and hypothalamus
(Homicsko et al. 2003). In fact, our present in vitro experi-
ments showed that salsolinol used in a low 50 lM concen-
tration in primary hippocampal cultures did not affect the
mitochondrial membrane potential; however, in the highest
dose of 500 lM, like glutamate, it produced the loss of
mitochondrial membrane potential. What is more, salsolinol
applied together with glutamate did not antagonize its tox-
icity connected with the dysfunction of mitochondrial
membrane (Fig. 6).
It is important to underline that our in vitro studies
performed on hippocampal primary cultures of both mice
and rats clearly indicate that neurotoxic action of the
highest investigated concentration of salsolinol (500 lM)
occurs via apoptosis. Beyond the verification of caspase-3
activity or LDH release, other markers of apoptosis, such
as the identification of apoptotic cells by Hoechst 33342
and calcein AM staining in the rat hippocampal cultures,
were assessed. We also observed a biphasic effect of
salsolinol, depending on its concentration, in Hoechst
33342 and calcein AM staining analysis. Salsolinol at
50 lM normalized the number of healthy living cells and
diminished the number of fragmented nuclei caused by
glutamic acid (Fig. 4c). However, salsolinol at 500 lM
elevated the glutamate-induced pro-apoptotic effect on
hippocampal cells (Fig. 4d).
The latter findings suggest that salsolinol may regulate
the function of dopamine neurons as a neurotransmitter and
may act as a mediator in the dopamine system (Naoi et al.
2004). Salsolinol antagonized behavioral action of L-DOPA
and apomorphine, a dopamine receptor agonist (Ginos and
Doroski 1979; Antkiewicz-Michaluk et al. 2000). Binding
studies demonstrated that salsolinol displaced [3H] apo-
morphine, but not dopamine D1 ([
3H]SCH23,390) and D2
([3H]spiperone) receptor antagonists, from their binding
sites, with effectiveness comparable to that of dopamine
(Antkiewicz-Michaluk et al. 2000). The above data suggest
that salsolinol may suppress dopaminergic transmission by
acting on the agonist binding sites of dopaminergic
receptors, which are different from neuroleptic binding
sites. Salsolinol showed antidopaminergic profile since it
induced only a weak effect on spontaneous locomotor
activity. Moreover, it efficiently antagonized behavioral
and biochemical effects of apomorphine and induced
muscle rigidity (Antkiewicz-Michaluk et al. 2000; Lorenc-
Koci et al. 2000; Vetulani et al. 2001).
Our ex vivo studies provided further interesting infor-
mation about the mechanism of salsolinol action depending
on the concentration. The present biochemical analysis
demonstrated that a single dose of salsolinol (100 mg/kg)
produced no changes in the concentration of dopamine and
its metabolites in different rat brain structures. Its chronic
(14 consecutive days) administration did not produce any
changes in dopamine concentration or in the level of its
metabolites, as well. On the other hand, as was recognized
so far, the administration of salsolinol jointly with L-DOPA
enhanced its effect. In fact, the level of dopamine and all its
metabolites was significantly higher compared to a group
treated with L-DOPA alone (data not shown). Additionally,
both acute and chronic (14 days) administrations of
salsolinol (100 mg/kg i.p.) did not affect the level of a-
synuclein and tyrosine hydroxylase measured with 3 or
24 h withdrawal (Figs. 7a, b, 8a, b). The results seem to be
consistent with the previously demonstrated salsolinol
physiological ability to be a potent stimulator of prolactin
(PRL) release (Toth et al. 2002; Hashizume et al. 2008,
2010), especially during lactation (Homicsko et al. 2003;
Misztal et al. 2010). The fact is that PRL secretion is under
the dominant and tonic inhibitory control of DA, and there
is no consensus about the nature and identity of physio-
logically relevant PRL-releasing factors. However, it has
been demonstrated that salsolinol, a DA-derived com-
pound, is a putative endogenous regulator of PRL release in
rats. Salsolinol administration to freely moving rats dose-
dependently increased plasma concentrations of PRL; in
addition, stress- and suckling-induced release of PRL in
rats was blocked by an antagonist of salsolinol (1MeDIQ).
The studies of Hashizume et al. (2008, 2009) have shown
that intravenous (i.v.) injection of salsolinol stimulates the
release of PRL in adult female goats. Another research
group has also demonstrated that salsolinol is present in the
infundibular nucleus-median eminence in lactating sheep
and that the extracellular concentration of this compound
increases in response to a suckling stimulus, which is
associated with an increase in plasma PRL concentrations
(Misztal et al. 2008).
In summary, the presented study indeed indicates that
salsolinol might exert the opposing effects in the brain
310 Neurotox Res (2015) 27:300–313
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depending on the applied concentration. It reveals neuro-
protective activity in a low concentrations and pro-apop-
totic effects in the higher one. However, this naturally
occurring THIQ amine used in high concentration and
upon prolonged exposure causes apoptotic cell death and
can be one of the etiological factors of neurogenerative
disease.
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